**CVS Health Financial Overview: Q2 2026**
CVS Health reported a strong balance sheet for the first half of 2026, highlighting an operating cash flow of approximately $10.6 billion year-to-date and a cash reserve of about $2.7 billion as of the end of Q2. The company’s leverage ratio stood at around 3.5 times, with expectations of improvement as CVS raised its full-year cash flow outlook to at least $11.5 billion. Year-to-date, CVS has returned over $1.7 billion to shareholders through dividends, but it has taken a cautious approach to share repurchases, focusing on reducing leverage first.
**Peer Performance Snapshot**
Align Technology ended Q2 2026 with $1.1 billion in cash and cash equivalents and an operating cash flow of $192.8 million. The company repurchased roughly 393,400 shares for $67 million during the quarter. Cardinal Health reported $4.9 billion in cash with $5.0 billion of adjusted free cash flow, including $1.4 billion in share repurchases for the year and an increased buyback authorization of $5.0 billion.
**Stock Performance Trends**
CVS Health shares have risen 31.1% over the past year, outpacing the industry average growth of 10.8%. Currently, CVS trades at a forward price-to-sales ratio of 0.29, below the industry average of 0.50, and carries a Zacks Rank #2 (Buy).
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
